Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SRM 003

Drug Profile

SRM 003

Alternative Names: SHP-613; SRM003; Vascugel

Latest Information Update: 15 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer Shire
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral vascular disorders
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Peripheral arterial disorders; Peripheral vascular disorders

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 17 Jul 2014 Discontinued - Phase-II for Peripheral vascular disorders in USA (Implant)
  • 23 Jul 2013 Shire restarts enrolment in two phase II trials for Peripheral vascular disorders (haemodialysis access) in USA (NCT01806545, NCT01806584)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top